Aurobindo Pharma’s arm enters into agreement with Advent Pharma
Aurobindo Pharma’s wholly owned subsidiary — Aurobindo Pharma USA Inc. — has entered into an agreement to acquire a product under development and related assets from Advent Pharmaceuticals Pty, Australia, through AuroScience Pty, Melbourne, a 100% subsidiary of Aurobindo Pharma USA Inc.
This acquisition will provide an opportunity to acquire assets that would be used for specialty generics business and this acquisition will also lead to enhancement of R&D capabilities in complex specialty generics.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.